914-P: Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitors and Nephrolithiasis—An Updated Meta-analysis

IF 7.5 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Diabetes Pub Date : 2025-06-13 DOI:10.2337/db25-914-p
ZOHA SHAHZAD, OSAMA IJAZ, BADR ILMAGUOOK, RAHILA ALI, SADIA S. USMANI, ARSLAN A. KHAN, SAEEDA YASMIN, ABDUL MOIZ, FNU SAMRAH
{"title":"914-P: Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitors and Nephrolithiasis—An Updated Meta-analysis","authors":"ZOHA SHAHZAD, OSAMA IJAZ, BADR ILMAGUOOK, RAHILA ALI, SADIA S. USMANI, ARSLAN A. KHAN, SAEEDA YASMIN, ABDUL MOIZ, FNU SAMRAH","doi":"10.2337/db25-914-p","DOIUrl":null,"url":null,"abstract":"Introduction and Objective: SGLT-2i are effective in treating type 2 diabetes (T2DM), promoting weight loss, reducing blood pressure, and lowering cardiovascular risk. Diabetes increases nephrolithiasis risk due to urine acidification and elevated oxalate concentrations. This meta-analysis evaluates the impact of SGLT-2i on nephrolithiasis incidence. Methods: A comprehensive search of Medline, Embase, Google Scholar, Cochrane CENTRAL, Scopus, and clinicaltrials.gov was conducted through November 2024. We included observational studies and RCTs comparing SGLT-2i to other diabetes medications or placebo. The primary outcome was nephrolithiasis incidence after treatment. A random-effects meta-analysis was performed to calculate the pooled odds ratio (OR). Results: Twenty-eight studies (75,371 participants) met the inclusion criteria. The pooled analysis showed that SGLT-2i significantly reduced the risk of nephrolithiasis compared to other medications or placebo (OR: 0.90; 95% CI: 0.83-0.98; p=0.02; I²=0%). This contrasts with a previous meta-analysis that found no association between SGLT-2i and nephrolithiasis. Conclusion: This updated meta-analysis shows that SGLT-2i reduce nephrolithiasis risk in T2DM, suggesting potential benefit for those with recurrent nephrolithiasis. These findings highlight the broader therapeutic benefits of SGLT-2i beyond glucose control. Disclosure Z. Shahzad: None. O. Ijaz: None. B. Ilmaguook: None. R. Ali: None. S.S. Usmani: None. A.A. Khan: None. S. Yasmin: None. A. Moiz: None. F. Samrah: None.","PeriodicalId":11376,"journal":{"name":"Diabetes","volume":"13 1","pages":""},"PeriodicalIF":7.5000,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2337/db25-914-p","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction and Objective: SGLT-2i are effective in treating type 2 diabetes (T2DM), promoting weight loss, reducing blood pressure, and lowering cardiovascular risk. Diabetes increases nephrolithiasis risk due to urine acidification and elevated oxalate concentrations. This meta-analysis evaluates the impact of SGLT-2i on nephrolithiasis incidence. Methods: A comprehensive search of Medline, Embase, Google Scholar, Cochrane CENTRAL, Scopus, and clinicaltrials.gov was conducted through November 2024. We included observational studies and RCTs comparing SGLT-2i to other diabetes medications or placebo. The primary outcome was nephrolithiasis incidence after treatment. A random-effects meta-analysis was performed to calculate the pooled odds ratio (OR). Results: Twenty-eight studies (75,371 participants) met the inclusion criteria. The pooled analysis showed that SGLT-2i significantly reduced the risk of nephrolithiasis compared to other medications or placebo (OR: 0.90; 95% CI: 0.83-0.98; p=0.02; I²=0%). This contrasts with a previous meta-analysis that found no association between SGLT-2i and nephrolithiasis. Conclusion: This updated meta-analysis shows that SGLT-2i reduce nephrolithiasis risk in T2DM, suggesting potential benefit for those with recurrent nephrolithiasis. These findings highlight the broader therapeutic benefits of SGLT-2i beyond glucose control. Disclosure Z. Shahzad: None. O. Ijaz: None. B. Ilmaguook: None. R. Ali: None. S.S. Usmani: None. A.A. Khan: None. S. Yasmin: None. A. Moiz: None. F. Samrah: None.
914-P:钠-葡萄糖共转运蛋白2 (SGLT2)抑制剂和肾结石——一项最新的荟萃分析
简介和目的:SGLT-2i治疗2型糖尿病(T2DM)有效,促进体重减轻,降低血压,降低心血管风险。糖尿病由于尿液酸化和草酸盐浓度升高而增加肾结石的风险。本荟萃分析评估了SGLT-2i对肾结石发病率的影响。方法:综合检索Medline、Embase、谷歌Scholar、Cochrane CENTRAL、Scopus和clinicaltrials.gov,检索截止至2024年11月。我们纳入了比较SGLT-2i与其他糖尿病药物或安慰剂的观察性研究和随机对照试验。主要观察指标是治疗后肾结石的发生率。随机效应荟萃分析计算合并优势比(OR)。结果:28项研究(75,371名受试者)符合纳入标准。合并分析显示,与其他药物或安慰剂相比,SGLT-2i显著降低了肾结石的风险(or: 0.90;95% ci: 0.83-0.98;p = 0.02;²= 0%)。这与之前的荟萃分析形成对比,该分析发现SGLT-2i与肾结石之间没有关联。结论:这项最新荟萃分析显示,SGLT-2i可降低T2DM患者肾结石的风险,提示复发性肾结石患者可能受益。这些发现强调了SGLT-2i在血糖控制之外的更广泛的治疗益处。Z. Shahzad:没有。O. Ijaz:没有。B. Ilmaguook:没有。阿里:没有。s·s·乌斯马尼:没有。A.A.汗:没有。雅思敏:没有。A.莫伊兹:没有。F.萨姆拉:没有。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Diabetes
Diabetes 医学-内分泌学与代谢
CiteScore
12.50
自引率
2.60%
发文量
1968
审稿时长
1 months
期刊介绍: Diabetes is a scientific journal that publishes original research exploring the physiological and pathophysiological aspects of diabetes mellitus. We encourage submissions of manuscripts pertaining to laboratory, animal, or human research, covering a wide range of topics. Our primary focus is on investigative reports investigating various aspects such as the development and progression of diabetes, along with its associated complications. We also welcome studies delving into normal and pathological pancreatic islet function and intermediary metabolism, as well as exploring the mechanisms of drug and hormone action from a pharmacological perspective. Additionally, we encourage submissions that delve into the biochemical and molecular aspects of both normal and abnormal biological processes. However, it is important to note that we do not publish studies relating to diabetes education or the application of accepted therapeutic and diagnostic approaches to patients with diabetes mellitus. Our aim is to provide a platform for research that contributes to advancing our understanding of the underlying mechanisms and processes of diabetes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信